Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Erasca Inc. Common Stock
ERAS | US
15.76
USD0.29
1.87%
ERAS | US
About Erasca Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
15.76
Open
15.60
High
15.89
Low
14.96
Erasca Inc. a clinical-stage biopharmaceutical company focuses on discovering developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007 an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer colorectal cancer and acute myeloid leukemia; and ERAS-601 an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801 a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego California.
View LessERAS | US
Risk
52.0
Sharpe
10.16
Luna's Score
66/100
Recommendation
Buy
Luna says (ERAS | US)
What's Working
Positive Momentum
Strength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
What's not Working
High 6-Month Volatility (>65%)
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
50.2%1 month
52.0%3 months
116.7%6 months
100.4%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.75
Debt to equity
0.12
Debt to assets
0.10
Ent. to EBITDA
-1.57
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-143.95M
MarketCap
4.28B
MarketCap(USD)
4.28B
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-38.90
Short ratio
12.22
Short perc.
13.56
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
3.32
Range1M
4.57
Range3M
12.82
Volumes: Market Activity
Rel. volume
1.10
Price X volume
65.52M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.57 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.75 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 116.75 | 72.80 | Riskier |
| Debt to Equity | 0.12 | -1.23 | Expensive |
| Debt to Assets | 0.10 | 0.25 | Cheaper |
| Market Cap | 4.28B | 3.66B | Par |
